The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.

Slides:



Advertisements
Similar presentations
Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs E. Efthimiou, S Mudan E. Efthimiou, S Mudan On behalf of the Sarcoma Group.
Advertisements

CARBON ION THERAPY FOR SACRAL CHORDOMAS
Danny Indelicato, MD CTOS 2012 Ewing Sarcoma of the Axial Skeleton: Early Outcomes from the University of Florida Proton Therapy Program.
IMRT, Designed with Evidence-Based Bone Avoidance Objectives, Reduces the risk of Bone Fracture in the management of Extremity Soft Tissue Sarcoma Colleen.
CTOS, Boca Raton, 2005 A Radiation Treatment Planning Comparison for Lower Extremity Soft Tissue Sarcoma: Can the Future Surgical Wound Be Spared? Anthony.
In-Depth Analysis of Wound Complications Following Preoperative Radiotherapy for Lower Extremity Soft Tissue Sarcoma Patients Colleen Dickie MSc, MRT(T)(MR)
Primary thoracic sarcomas: prognostic factors and outcome in a series of patients treated at a single institution Leonardo Duranti T horacic Surgery.
Frontline Aggressive Surgical Approach To Primary Retroperitoneal STS: A Morbidity / Mortality Analysis From A Multi-Institutional Retrospective Review.
Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.
Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.
Value of local treatment in extrapulmonary metastatic Ewing sarcoma
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.
GOS Paediatric Sarcoma Surgery Combined UCL Sarcoma Service GOS Oncology and London Bone and Soft Tissue Tumour Service UCLH.
IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.
Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Hot topics in breast radiotherapy Mark Beresford.
Thomas F. DeLaney MD, Aashish D. Bhatt MD, Alex Jacobson BS, Richard Y. Lee MD, PhD, Christine Giraud BS, Joseph H. Schwab MD, MS, Francis J. Hornicek.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.
Prof Ramesh S Bilimagga President AROI Group Medical Director - HCG.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
Margin Reduction using IGRT For Soft-Tissue Sarcoma: Secondary Analysis of RTOG 0630 Dian Wang, MD., Ph.D. Rush University Medical Center CTOS October.
CTOS 2013 Radiation Oncology Session Discussion Elizabeth H Baldini, MD, MPH Associate Professor of Radiation Oncology Harvard Medical School Brigham and.
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,
Kerrington Smith, M.D. CTOS Nov 14, 2008
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
Post-Resection CA 19-9 Predicts Overall Survival in Patients Treated with Adjuvant Chemoradiation; RTOG 9704 A. Berger, K. Winter, J. Hoffman, W. Regine,
Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,
Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas Ryan M. Lanning, Sean L. Berry, Michael.
An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.
Adductor Compartment STS - Does method of treatment affect outcome? Anup Pradhan, Yiu-Chung Cheung Birmingham Medical School, UK Supervisors: Mr Robert.
Quantifying the Morbidity of the Unplanned Sarcoma Excision
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
Five year results of a randomized Phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma Brian O'Sullivan, Aileen.
EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.
Per-Ulf Tunn, D. Andreou, S. Fehlberg, M. Werner, P. Reichardt
Chiba Cancer Center, Chiba, Japan Shintaro Iwata Tsukasa Yonemoto Yoko Hagiwara Takeshi Ishii Division of Orthopedic Surgery Akinobu Araki Dai Ikebe Division.
LCC REC-1 Φ π π π Φ Φ See Primary and Adjuvant Treatment (LCC REC-3) Observe or See Primary Treatment (LCC REC-3) Rectal Cancer.
Symposium 2: Sarcoma of the Year – Synovial Sarcoma Peter Reichardt HELIOS Klinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg.
Jens Jakob 1 ; Anna Simeonova 2 ; Bernd Kasper 3 ; Ulrich Ronellenfitsch 1 ; Frederik Wenz 2 ; Peter Hohenberger 1 1 Department of Surgery, 2 Department.
CTOS, Berlin 2014 The influence of time interval between preoperative radiation and surgical resection on the development of wound healing complications.
CTOS years Experience of Management of Malignant Phyllodes Tumor and Breast Sarcoma at Princess Margaret Hospital Princess Margaret Hospital &
Radiation Therapy Connective Tissue Oncology Society 2005 Thomas F. DeLaney, M.D.
Malignancy Grade and Histologic Subtype of Primary Retroperitoneal Sarcoma (RPS) are Predictive of Pattern of Recurrence: a Large Retrospective Study from.
14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.
Local Recurrence Growth Rate Predicts Outcome In Locally Recurrent Retroperitoneal Liposarcoma James Park, MD, Li-Xuan Qin, PhD, Francesco Prete, MD Murray.
M ETHODS Median dose was 22Gy (range: ) in 1 to 5 fractions Median treatment volume was 12.6 cc (range: ). Assessed for eligibility.
Operative Management of Osteosarcoma Patients with Pulmonary Metastasis Jen Kramer, MD R2 Swedish Medical Center February 2011.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.
University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.
Results of Definitive Radiotherapy in Anal Canal Carcinoma
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
Prognosis of younger patients in non-small cell lung cancer
Institute of Oncology “Ion Chiricuță”, Cluj, Romania
Osteosarcoma Jessica Davis.
Authors: Nahhas, Mohammed, and Isler, Marc
PRIMARY EXTREMITY STS: MULTIMODAL APPROACH MAY HAVE IMPROVED SURVIVAL
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
HISTOLOGY-SPECIFIC NOMOGRAM FOR PATIENTS AFFECTED BY PRIMARY RSTS
Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program
Prognosis of angiosarcoma at different anatomic sites
Presentation transcript:

The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center

Introduction: STS & Age Wibmer C et al. Ann Oncol 2009

Local Recurrence & Age Cahlon O et al. ASTRO 2008

Use of RT and Older Age: MSKCC Data (n = 1459) Odds Ratio 95% CI p value Limb sparing surgery < High grade < Deep tumor < Size ≥ 5 cm < Positive margin Age ≥ Ashman et al. ASTRO 2006

Purpose To determine whether older age, defined as ≥ 70 years, influences morbidity in pts with primary HG extremity STS who received adjuvant RT at MSKCC

Patient Population  # of pts: 433  Period: 8/82- 02/06  Presentation: Primary, N0M0  Mean age: 53 (range: 16-89)  Grade: High only  Deep: 89% (n = 387)  Size > 5 cm: 74% (n = 322)  Lower extremity: 72% (n = 310)

Extent of Surgery All pts had limb-sparing surgery at MSKCC n % Bone manipulation ♠ Nerve manipulation ♦ Tissue transfer 31 7 ♠: Periosteal stripping/bone resection ♦: Neurolysis/nerve resection

RT Type All pts had their RT MSKCC n (%) Dose (Gy)* BRT 239 (55%) 45 EBRT 159 (37%) 63 BRT+EBRT 35 (8%) Adjuvant chemotherapy: 139/433 (32%). *: Median dose

Sex Female Male 159 (47%) 180 (53%) 41(44%) 53 (56%) 0.5 Size (cm) ≤ 5 > 5 85 (25%) 254 (75%) 26 (28%) 68 (72%) 0.6 Depth Superficial Deep 33 (10%) 306 (90%) 13 (14%) 81 (86%) 0.25 Site Upper extremity Lower extremity 94 (28%) 245 (72%) 29 (31%) 65 (69%) 0.5 Adjuvant CT Yes No 127 (38%) 212 (62%) 12 (13%) 82 (87%) < 70 ≥ 70 p Distribution of Variables

Extent of Surgery & Age Groups < 70 (n = 339)≥ 70 (n = 94)p Bone manipulation ♠ 63 (18%)20 (21%)0.5 Nerve manipulation ♦ 97 (29%)18 (19%)0.06 Tissue transfer 28 (8%)3 (3%)0.2 ♠: Periosteal stripping/bone resection ♦: Neurolysis/nerve resection

RT Type & Age Groups: For the purpose of this analysis, BRT and BRT+EBRT were combined < 70 (n = 339)≥ 70 (n = 94)p BRT/BRT+EBRT 220 (65%)54 (57%) EBRT 119 (35%)40 (43%) 0.18

RT “Conventional” Dose & Age Groups Conventional: BRT 45 Gy EBRT Gy BRT+EBRT and Gy < 70 (n = 339)≥ 70 (n = 94)p BRT* 200 (91%)50 (93%)0.15 EBRT 108 (91%)35 (88%)0.2 *: BRT and BRT+EBRT

Morbidity Median F/U: 53 months n (%) Wound re-operation 33 8 Fracture 17 4 Stiffness Edema Nerve Damage ♠ 27 7 ♠:Those with nerve resection were excluded

Morbidity & Age < 70 ≥ 70 p Wound re-operation 7% 12% 0.09 Fracture 4% 3% 0.6 Stiffness 11% 15% 0.3 Edema 9% 18% 0.01 Nerve Damage ♠ 8% 4% 0.13 ♠:Those with nerve resection were excluded

Joint Stiffness n (%) Grade Grade Grade Grade 3 5 1

Grade of Stiffness & Age Groups < 70 (n = 339)≥ 70 (n = 94) Grade (89%)80 (85%) Grade 119 (6%)7 (7%) Grade 2 14 (4%)6 (6%) Grade 3 4 (1%)1 (1%)

Edema n (%) Grade Grade Grade Grade 3 5 1

Grade of Edema & Age Groups < 70 (n = 339)≥ 70 (n = 94) Grade (91%)79 (84%) Grade 113 (4%)4 (4%) Grade 2 15 (4%)9 (10%) Grade 3 3 (1%)2 (2%)

Grade of Nerve Damage: (n = 377/433) ♠ n (%) Grade Grade Grade Grade Grade ♠:Those with nerve resection were excluded

Grade of Nerve ♠ Damage & Age Groups < 70 (n = 291)≥ 70 (n = 86) Grade (92%)83 (97%) Grade 19 (3%)2 (2%) Grade 2 6 (1.5%)1 (1%) Grade 3 1 (0.5%)0 (0%) Grade 48 (3%)0 (0%) ♠:Those with nerve resection were excluded

Conclusion  Older age (≥ 70 years) is not associated with increased morbidity from treatment with the exception of edema  Strategies to minimize the risk of edema are warranted  Withholding adjuvant RT solely based on older age, for fear of potential morbidity doesn’t seem to be justified

Influence of Age on BRT Morbidity < 70 ≥ 70 p Wound re-operation 9% 11% 0.7 Fracture 2% 0.8 Stiffness 5% 6% 0.8 Edema 6% 11% 0.2 Nerve Damage ♠ 8% 2% 0.2 ♠:Those with nerve resection were excluded

Influence of Age on EBRT Morbidity < 70 ≥ 70 p Wound re-operation 3% 13% 0.03 Fracture 8% 5% 0.8 Stiffness 22% 28% 0.6 Edema 14% 28% 0.09 Nerve Damage ♠ 10% 6% 0.7 ♠:Those with nerve resection were excluded

Morbidity & Type of RT in < 70 BRT EBRT p Wound re-operation 9% 3% 0.05 Fracture 2% 8% 0.03 Stiffness 5% 22% Edema 6% 14% Nerve Damage ♠ 8% 10% 0.7 ♠:Those with nerve resection were excluded

Morbidity & Type of RT in ≥ 70 BRT EBRT p Wound re-operation 11% 13% 0.9 Fracture 2% 5% 0.7 Stiffness 6% 28% Edema 11% 28% 0.07 Nerve Damage ♠ 1% 6% 0.7 ♠:Those with nerve resection were excluded

RT Type & Age Groups < 70 (n = 339)≥ 70 (n = 94)p BRT 188 (56%)51 (54%) EBRT 119 (35%)40 (43%)0.18 BRT + BRT 32 (9%)3 (3%)